D.E. Shaw & Co
KURA icon

D.E. Shaw & Co’s Kura Oncology KURA Stock Holding History

D.E. Shaw & Co’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-140,713
Closed -$812K – 4763
2025
Q2 		$812K Sell
140,713
-278,275
-66% -$1.7M ﹤0.01% 3374
2025
Q1 		$2.77M Sell
418,988
-732,207
-64% -$5.71M ﹤0.01% 2366
2024
Q4 		$10M Buy
1,151,195
+727,987
+172% +$10.5M 0.01% 1491
2024
Q3 		$8.27M Buy
423,208
+47,474
+13% +$962K 0.01% 1554
2024
Q2 		$7.74M Sell
375,734
-14,168
-4% -$291K 0.01% 1509
2024
Q1 		$8.32M Buy
389,902
+184,282
+90% +$3.58M 0.01% 1500
2023
Q4 		$2.96M Sell
205,620
-1,480
-0.7% -$14.6K ﹤0.01% 2346
2023
Q3 		$1.89M Sell
207,100
-5,043
-2% -$51.2K ﹤0.01% 2609
2023
Q2 		$2.24M Buy
212,143
+42,063
+25% +$497K ﹤0.01% 2546
2023
Q1 		$2.08M Sell
170,080
-7,755
-4% -$96.8K ﹤0.01% 2665
2022
Q4 		$2.21M Sell
177,835
-101,624
-36% -$1.48M ﹤0.01% 2865
2022
Q3 		$3.82M Buy
279,459
+188,559
+207% +$2.91M ﹤0.01% 2380
2022
Q2 		$1.67M Buy
90,900
+27,002
+42% +$388K ﹤0.01% 3226
2022
Q1 		$1.03M Sell
63,898
-95,036
-60% -$1.37M ﹤0.01% 3899
2021
Q4 		$2.23M Buy
158,934
+23,929
+18% +$388K ﹤0.01% 3265
2021
Q3 		$2.53M Sell
135,005
-164,005
-55% -$3.09M ﹤0.01% 2812
2021
Q2 		$6.23M Sell
299,010
-48,180
-14% -$1.2M 0.01% 1865
2021
Q1 		$9.81M Sell
347,190
-233,403
-40% -$7.38M 0.01% 1368
2020
Q4 		$19M Buy
580,593
+240,962
+71% +$8.47M 0.02% 983
2020
Q3 		$10.4M Buy
339,631
+76,174
+29% +$1.68M 0.01% 1216
2020
Q2 		$4.29M Buy
263,457
+89,617
+52% +$1.29M 0.01% 1764
2020
Q1 		$1.73M Sell
173,840
-89,380
-34% -$1.02M ﹤0.01% 2288
2019
Q4 		$3.62M Buy
263,220
+67,322
+34% +$998K ﹤0.01% 1999
2019
Q3 		$2.97M Buy
195,898
+113,894
+139% +$2.03M ﹤0.01% 2060
2019
Q2 		$1.61M Buy
+82,004
New +$1.36M ﹤0.01% 2382

Other funds holding KURA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

D.E. Shaw & Co's KURA Position: Q3 2025 in Review

D.E. Shaw & Co sold out of Kura Oncology (KURA) in Q3 2025, closing a stake of 140,713 shares — an estimated $812K sold.

D.E. Shaw & Co first reported a position in KURA in Q2 2019 and held it in 25 quarters. The position peaked at $19M in Q4 2020. 200 funds tracked by Wall St. Rank hold KURA as of Q3 2025.

  • D.E. Shaw & Co reported no remaining Kura Oncology position as of Q3 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 140,713 Kura Oncology shares in Q3 2025, an estimated $812K.
  • D.E. Shaw & Co first reported a position in Kura Oncology in Q2 2019 and held it in 25 quarters.
  • D.E. Shaw & Co's Kura Oncology position peaked at $19M in Q4 2020.
  • 200 funds tracked by Wall St. Rank held Kura Oncology as of Q3 2025.

Based on D.E. Shaw & Co's 13F filing for Q3 2025, filed 14 Nov 2025.